Robinson Elizabeth
Known title: DirectorCIK: 0001687218
Associated companies
Transaction History
| BNY | ▲ Buy | Grant | 73 | $11K | 7/1/2026 | View on chart |
| BNY | ▲ Buy | Grant | 88 | $11K | 4/1/2026 | View on chart |
| BNY | ▲ Buy | Grant | 87 | $11K | 2/2/2026 | View on chart |
| BNY | ▲ Buy | Grant | 99 | $11K | 10/1/2025 | View on chart |
| BNY | ▲ Buy | Grant | 117 | $11K | 7/1/2025 | View on chart |
| BNY | ▲ Buy | Grant | 127 | $11K | 4/1/2025 | View on chart |
| BNY | ▲ Buy | Grant | 110 | $9K | 2/3/2025 | View on chart |
| BNY | ▲ Buy | Grant | 132 | $9K | 10/1/2024 | View on chart |
| BNY | ▲ Buy | Grant | 156 | $9K | 7/1/2024 | View on chart |
| BNY | ▲ Buy | Grant | 165 | $9K | 4/1/2024 | View on chart |
| BNY | ▲ Buy | Grant | 169 | $9K | 2/1/2024 | View on chart |
| BNY | ▲ Buy | Grant | 223 | $9K | 10/2/2023 | View on chart |
| BNY | ▲ Buy | Grant | 208 | $9K | 7/3/2023 | View on chart |
| BNY | ▲ Buy | Grant | 173 | $8K | 4/3/2023 | View on chart |
| BNY | ▲ Buy | Grant | 154 | $8K | 2/1/2023 | View on chart |
| BNY | ▲ Buy | Grant | 197 | $8K | 10/3/2022 | View on chart |
| BNY | ▲ Buy | Grant | 184 | $8K | 7/1/2022 | View on chart |
| BNY | ▲ Buy | Grant | 158 | $8K | 4/1/2022 | View on chart |
| BNY | ▲ Buy | Grant | 127 | $8K | 2/1/2022 | View on chart |
| BNY | ▲ Buy | Grant | 148 | $8K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BNY Q3 Earnings Show Margin Gains and Raised Outlook
Bank of New York Mellon reported third-quarter results that highlighted margin improvements and a raised outlook, with a focus on AI initiatives. While the market reaction was muted, analysts noted the earnings beat. One firm maintained its stance but lowered its price target to $165, reflecting a cautious view despite the positive fundamentals.
BNY Q3 Earnings Show Margin Gains and Raised Outlook. Bank of New York Mellon reported third-quarter results that highlighted margin improvements and a raised outlook, with a focus on AI initiatives. While the market reaction was muted, analysts noted the earnings beat. One firm maintained its stance but lowered its price target to $165, reflecting a cautious view despite the positive fundamentals.